Cargando…
Recycling the Purpose of Old Drugs to Treat Ovarian Cancer
The main challenge in ovarian cancer treatment is the management of recurrences. Facing this scenario, therapy selection is based on multiple factors to define the best treatment sequence. Target therapies, such as bevacizumab and polymerase (PARP) inhibitors, improved patient survival. However, des...
Autores principales: | Nunes, Mariana, Henriques Abreu, Miguel, Bartosch, Carla, Ricardo, Sara |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7656306/ https://www.ncbi.nlm.nih.gov/pubmed/33092251 http://dx.doi.org/10.3390/ijms21207768 |
Ejemplares similares
-
Editorial: New molecular approaches to improve gynecological cancer management
por: Abreu, Miguel Henriques, et al.
Publicado: (2023) -
Impressive and durable clinical responses obtained with dabrafenib and trametinib in low-grade serous ovarian cancer harbouring a BRAF V600E mutation
por: Lima, Bárbara, et al.
Publicado: (2022) -
Do Not Forget Poly (Adenosine Diphosphate-Ribose) Polymerase Inhibitors in Ovarian Carcinosarcoma
por: Magalhães, Denise, et al.
Publicado: (2022) -
Research Perspective: Potential Role of Nitazoxanide in Ovarian Cancer Treatment. Old Drug, New Purpose?
por: Di Santo, Nicola, et al.
Publicado: (2013) -
Recycling Old Antibiotics with Ionic Liquids
por: Prudêncio, Cristina, et al.
Publicado: (2020)